June 24, 2024
Action The U.S. Food and Drug Administration has approved Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP) in adults. Vyvgart […]
June 24, 2024
TOPLINE: Researchers sought to better understand the risk for recurrence and precipitants for relapse in anterior uveitis, potentially allowing clinicians to better provide a prognosis and […]
June 24, 2024
Several new studies in lung cancer have opened their doors recently. Is one of your patients eligible to participate? Resected stage II, IIIA, or IIIB with […]
June 24, 2024
TOPLINE: Poor vision and contrast sensitivity at baseline increase the likelihood of incident dementia in older adults; a decline in contrast sensitivity over time also correlates […]
June 24, 2024
LYON, France — Bempedoic acid (Nexletol) is safe for people with obesity and is effective at lowering lipid levels and rates of major cardiovascular events, according […]
June 24, 2024
In 2017, CDER began the modernization of the New Drugs Regulatory Program (NDRP), a multi-year framework to increase the efficiency and effectiveness of CDER offices. The […]
June 24, 2024
PARIS — Despite some potential advantages, transcatheter aortic valve implantation (TAVI) failed to meet the primary prespecified threshold for noninferiority to surgical aortic valve replacement in […]
June 24, 2024
New research found women aged 21-65 years who were due for a Papanicolaou (Pap) test to screen for cervical cancer were about 30% less likely in […]
June 24, 2024
(Reuters) – G1 Therapeutics said on Monday its drug for a rare, aggressive form of breast cancer did not meet the main goal of overall survival […]
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447448449450451452453454455456457458459460461462463464465466467468469470471472473474475476477478479480481482483484485486487488489490491492493494495496497498499500501502503504505506507508509510511512513514515516517518519520521522523524525526527528529530531532533534535536537538539540541542543544545546547548549550551552553554555556557558559560561562563564565566567568569570571572573574575576577578579580581582583584585586587588589590591592593594595596597598599600601602603604605606607608609610611612613614615616617618619620621622623
Next page